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Inflammation is a fundamentally protective process that protects the host from invading 
pathogens and it is central in the repair and regeneration of damaged tissue. However when 
uncontrolled, the overzealous response leads to tissue damage and malaise. Indeed, this 
process is now appreciated to be at the center of many chronic diseases including vascular 
disease and arthritis. Studies investigating the mechanisms through which acute inflammation is 
actively turned off to allow the tissue to regain function demonstrated that in inflammatory 
exudates the essential fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) are enzymatically converted to bioactive mediators. These mediators carry distinct 
structures actively, reprogram the inflammatory reaction to promote its termination, counter-
regulate the production of pro-inflammatory mediators and regulate leukocyte trafficking as well 
as phenotype. Recently we found that n-3 docosapentaenoic acid, which was until then only 
regarded as a biosynthetic intermediate in the formation of DHA from EPA, is also converted to 
structurally distinct bioactive mediators that reprogram the host immune response. In the 
present review we will discuss the evidence underpinning the biological actions of these 




Success in the evolution of multicellular organisms was, at least in part, reliant on the 
development of a system to repair and regenerate damaged tissues as well as to defend the 
organism from invading microbial pathogens [1]. This defense system is embodied in the 
inflammatory process which when self-limited is fundamentally protective and coordinates both 
the killing and disposal of invading pathogens as well as the repair and regeneration of 
damaged tissues [2]. However, when this process becomes dysregulated it leads to disease [3-
7]. Pioneering studies investigating mechanisms that regulate the termination of inflammation 
uncovered a new genus of mediators produced via the stereoselective conversion of essential 
fatty acids, termed as specialized pro-resolving mediators (SPM) [8]. This superfamily includes 
the arachidonic acid (AA)-derived lipoxins, the eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) resolvins [9], and the DHA-derived protectins [10] and maresins 
[11]. These mediators share select biological actions that include i) limiting neutrophil 
recruitment to the site of inflammation, ii) they counter-regulate the production of pro-
inflammatory mediators including prostaglandins, leukotrienes, cytokines and chemokines (e.g. 
Tumor necrosis factor alpha), iii) promote the uptake and killing of bacteria and iv) increase the 
uptake and clearance of apoptotic cells [3-6,8]. In addition, each of the mediators exerts unique 
biological actions for example, the EPA-derived resolvin E1 regulates platelet activation [12], the 
DHA-derived protectins regulate viral replication [13] and the DHA-derived maresins promote 
tissue regeneration [3,14].  
SPM exert their potent biological actions via the activation of specific G-protein coupled 
receptors which include the Lipoxin A4 receptor (ALX/FPR2), GPR32/DRV1, GPR18/DRV2 and 
the chemerin receptor ChemR23/ERV1 [15]. In addition to activating cognate receptors, these 
protective mediators also regulate the onset and propagation of inflammatory responses by 
acting as partial agonists or antagonists to receptors of inflammatory mediators including BLT-1, 
the Leukotriene (LT)B4 (5S,12R-dihydroxy- 6Z,8E,10E,14Z- eicosatetraenoic acid) receptor [16], 
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and cysLT1 the receptor for LTC4 (5S-hydroxy-6R-(S-glutathionyl)-7E,9E,11Z,14Z-
eicosatetraenoic acid) and LTD4(5S-hydroxy-6R-(S-cysteinylglycinyl)-7E,9E,11Z,14Z-
eicosatetraenoic acid) [16]. Studies investigating mechanisms involved in the onset and 
propagation of inflammatory disorders indicate defects in the production of the pro-resolving 
mediators, their enhanced further metabolism or defects in the signaling via their cognate 
receptors are linked with disease onset and/or progression [3-6,8].  
In mammals, the essential fatty acid alpha-linolenic acid (9Z, 12Z, 15Z-octadecatrienoic 
acid; ALA) is enzymatically elongated and desaturated to produce EPA and subsequently to 
DHA with n-3 docosapentaenoic acid (7Z,10Z,13Z,16Z,19Z-docosapentaenoic acid; n-3 DPA) 
being the biosynthetic intermediate in this process [17-19]. n-3 DPA contains a 22-carbon chain 
with 5 double bonds and differs from DHA as it lacks a cis-double bond at carbon 4, which, 
although a small change, provides its own specific biologically relevant actions [20,19]. These 
actions have been identified in a variety of mammalian tissues, including plasma, brain, retina 
and heart. Genome-wide association studies in humans uncovered a correlation between 
increases in peripheral blood n-3 DPA concentrations and single nucleotide polymorphisms in 
the gene encoding for the fatty acid elongase 2 (ELOVL2)[21]. We recently found that, in 
addition to EPA and DHA, n-3 DPA is substrate for conversion to novel families of bioactive 
mediators [20]. The aim of the present review is to discuss the actions of these novel families of 
mediators in regulating key leukocyte responses. 
 
n-3 DPA-derived SPM are novel resolution agonists 
Events that occur in the early phases of an inflammatory reaction are suggested to 
determine whether the response is self-limited or perpetuates and becomes chronic [22]. 
Assessment of events occurring within the circulation during acute self-limited inflammation 
demonstrated that the concentrations of n-3 DPA were rapidly upregulated during acute 
inflammation, to an extent that was comparable to essential fatty acids that are involved in the 
 5 
biosynthesis of lipid mediators, including arachidonic acid and DHA. Using a systematic 
approach coupling structure elucidation with functional readouts we found that endogenous n-3 
DPA is converted to bioactive mediators in both mice and human leukocytes that carried pro-
resolving properties [20]. These mediators are congenerous with DHA products, namely D-
series resolvins (RvDn-3 DPA), protectins (PDn-3 DPA) and maresins (MaRn-3 DPA), with unique 
stereochemistries [20]. In self resolving exudates, the production of these molecules was 
temporally regulated where for example RvD1n-3 DPA (7S,8R,17S-trihydroxy-9E,11E,13Z,15E,19Z 
-docosapentaenoic acid) and PD2n-3 DPA (16,17-dihydroxy-7Z,10,13, 14,19Z- docosapentaenoic 
acid) displayed a bi-phasic profile, reaching a maximum during peak neutrophil infiltration and 
late into resolution. PD1n-3 DPA (10R,17S-dihydroxy-7Z,11E,13E,15Z,19Z-docosapentaenoic 
acid), MaR2n-3 DPA (13,14-dihydroxy-7Z,9,11, 16Z,19Z-docosapentaenoic acid) and MaR3n-3 DPA 
(4, 21-dihydroxy-7Z,10Z,12E,16Z,19Z-docosapentaenoic acid) levels were each found to reach 
a maximum at the 4h interval and gradually decreased over the next 20 h. The peak in exudate 
RvD2n-3 DPA (7S,16,17S-trihydroxy-8,10Z,12,14,19Z-docosapentaenoic acid) levels coincided 
with the onset of resolution (the point where PMN levels reach ~50 of Tmax). RvD5n-3 DPA 
(7S,17S-dihydroxy-4Z,8,10Z,13Z,15,19Z-docosahexaenoic acid) levels were found to gradually 
increase over the course of inflammation-resolution, with a maximum being reached late in the 
resolution phase. The n-3 DPA product corresponding to MaR1n-3 DPA (7S,14S-dihydroxy-8E, 
10E, 12Z, 16Z, 19Z-docosapentaenoic acid) gave levels that were elevated in the peritoneum of 
naive mice, where upon challenge with zymosan these levels drastically decreased. MaR1n-3 DPA 
accumulated late during resolution [20]. Of note each of these molecules displayed leukocyte 
directed actions whereby incubation of human neutrophils with RvD5n-3 DPA or PD1n-3 DPA 
markedly reduced neutrophil adhesion to TNF-α activated endothelial cells and chemotaxis 
towards IL-8, to a similar extent as the DHA-derived RvD2 (7S,16R,17S-trihydroxy- 
4Z,8E,10Z,12E,14E,19Z- docosahexaenoic acid) [23,20,24]. These mediators regulate the 
expression of adhesion molecules on peripheral blood leukocytes and platelets including the 
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expression of CD11b on neutrophils and monocytes as well as CD62P and CD63 on platelets 
[25]. Furthermore, they also regulate the formation of leukocyte-platelet heterotypic aggregates 
in both human and mouse peripheral blood. The biological actions of these molecules extend 
beyond the regulation of mechanisms in leukocyte trafficking. Indeed, n-3 DPA-derived SPMs 
also regulate the uptake of apoptotic cells by macrophages, a key biological action in the 
resolution of inflammation, with increases in macrophage efferocytosis of up to 70% at doses as 
low as 1nM [23,20]. These mediators also display endothelial directed actions, counteracting the 
TNF-a- mediated upregulation of adhesion molecules, such as Intercellular Adhesion Molecule 
1 (ICAM-1/CD54), on endothelial cells [20]. 
 
Diurnal regulation of RvDn-3 DPA controls vascular leukocyte and platelet activation 
Circadian mechanisms are at the heart of a number of physiological functions, including 
leukocyte and platelet responses [26,27]. Disturbances to various aspects of these fundamental 
mechanisms are thought to be responsible for many of the diseases that afflict modern 
societies, including cardiovascular and metabolic disorders [26-28]. These conditions are 
characterized by a dysregulated inflammatory response, although the exact mechanisms that 
underlie this inflammatory state remain of interest. Recent studies demonstrate that the 
production of RvDn-3 DPA are diurnally regulated in the peripheral blood of healthy volunteers [25] 
(Figure 1). Multivariate analysis of plasma lipid mediator profiles demonstrated a diurnal shift in 
plasma LM-SPM concentrations with a leftward shift in LM-SPM clusters from morning to 
evening profiles. This shift was associated with an increase in the amounts of n-3 DPA derived 
mediators, including RvD1n-3 DPA and RvD5n-3 DPA from the evening (18:00 h) to morning intervals 
(7:00 and 9:00 h). These diurnal changes in peripheral blood RvDn-3 DPA concentrations were 
abrogated in mice lacking the main orchestrator of the molecular clock, BMAL1 in myeloid cells. 
Of note, the fluctuations in plasma RvDn-3 DPA were associated with a regulation of leukocyte and 
platelet activation that reaches a maximum between 7:00 and 9:00h coincident with an increase 
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in RvDn-3 DPA concentrations. The production of these mediators was found to be under the 
control of acetylcholine (ACh), with peripheral blood concentrations of this neurotransmitter also 
reaching a maximum during the early hours of the morning (i.e. 7:00h). Furthermore, incubation 
of whole blood with ACh increased RvDn-3 DPA concentrations, including RvD2n-3 DPA, under both 
static and flow conditions. 
Assessment of the production of these mediators in patients with cardiovascular disease 
(CVD) demonstrated significant decreases in plasma RvDn-3 DPA concentrations and a marked 
impairment in their diurnal regulation when compared with healthy volunteers. Flow cytometric 
analysis of peripheral blood leukocyte from patients with CVD demonstrated increases in the 
expression of CD11b on both neutrophils and monocytes when compared with healthy 
volunteers. This was coupled with increases in platelet–neutrophil and platelet–monocyte 
aggregates in peripheral blood from patients with CVD [25]. In addition, we found a significant 
relationship between peripheral blood RvDn-3 DPA concentration and leukocyte and platelet 
activation, as demonstrated by a negative correlation between RvDn-3 DPA and neutrophil CD41, 
monocyte CD41, and platelet CD63 and CD42b expression. Investigations into mechanisms 
that lead to the downregulation of peripheral blood RvDn-3 DPA mediators in patients with CVD 
demonstrated a link between peripheral blood adenosine concentrations and the activity of one 
of the RvDn-3 DPA biosynthetic enzymes, ALOX5. Adenosine, via the activation of the A2a 
receptor, downregulates the activity of ALOX5 [29], and in CVD patients we found that this 
nucleoside was upregulated in peripheral blood. The role of adenosine in downregulating RvDn-3 
DPA concentrations was further underscored by experiments where peripheral blood from CVD 
patients were incubated with adenosine deaminase, that lead to a significant restoration of 
peripheral blood RvD n-3 DPA concentrations [25]. 
These findings lead us to propose RvDn-3 DPA as endogenous protective signals that 
control physiological platelet and leukocyte activation. This is further supported by observations 
made in Apolipoprotein E deficient mice (ApoE-/-) mice fed a western diet. Treatment of these 
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mice with RvD5n-3 DPA reduced platelet-leukocytes aggregates in vivo and modulated vascular 
lipid mediator profiles reducing concentrations of the pro-thrombogenic mediator Thromboxane 
(Tx) A2 (measured as its metaboliteTxB2) and upregulating the formation of pro-resolving 
mediators including MaR1 (7S,14S-dihydroxy-4Z, 8E, 10E, 12Z, 16Z, 19Z-docosahexaenoic 
acid) and aspirin triggered (AT)-LXA4 (5S,6R,15R-trihydroxy-7E,9E,11Z,13E-eicosatetraenoic 
acid). Furthermore RvD5n-3 DPA also decreased early aortic lesions in ApoE-/- mice. The present 
findings are in line with published findings demonstrating an altered production of vascular DHA-
derived SPMs including RvD2 and MaR1 and impaired resolution responses in the 
pathogenesis of atherosclerosis [30,31]. Together these findings demonstrate that alterations in 
the diurnal regulation of vascular RvDn-3 DPA may occur early in the pathogenesis of 
cardiovascular diseases that results in vascular inflammation and impaired biosynthesis of DHA 
derived SPM.  
 
PDn-3 DPA regulates macrophage phenotype and function during monocyte to macrophage 
differentiation 
It is now well appreciated that in chronic inflammatory conditions, such as 
atherosclerosis and rheumatoid arthritis, monocytes play a central role in the initiation, 
propagation and termination of inflammation [32,33]. Upon recruitment to the site of 
inflammation, these cells either differentiate to inflammatory macrophages that propagate the 
inflammatory response or to resolution phase macrophages that promote the termination of 
inflammation and restitution of tissue function. Studies investigating mechanism that regulate 
the differentiation of macrophages demonstrate a role for the PDn-3 DPA pathway in regulating the 
phenotype and function of monocyte-derived macrophages [34] (Figure 2).  Using a total 
organic synthetic approach coupled with lipid mediator profiling, human ALOX15 and ALOX15B 
were identified as the enzymes that catalyse the first two steps in the PDn-3 DPA biosynthetic 
pathway yielding an allylic epoxide. Using total organic synthesis we established the absolute 
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stereochemistry of this epoxide as 16S,17S-epoxy-7Z,10Z,12E,14E,19Z-docosapentaenoic acid 
[34,35]. This intermediate was in turn converted to PD1n-3 DPA and PD2n-3 DPA by different epoxide 
hydrolase enzymes, where in human cells epoxide hydrolase 2 (EPHX2) was found to catalyse 
the conversion of 16S,17S-ePDn-3 DPA to PD2n-3 DPA. Experiments investigating the expression of 
the PDn-3 DPA biosynthetic pathway during monocyte to macrophage differentiation found the 
expression of all three enzymes was upregulated during monocyte to macrophage 
differentiation. Of note, ALOX15 expression was higher in M2 differentiated cells, whereas the 
expression of ALOX15B was higher in M1 cells [34].  
Pharmacological inhibition and genetic deletion of ALOX15 enzymes in monocytes led to 
phenotypic and functional changes in monocyte-derived macrophages. In cells where ALOX15 
was inhibited there was a downregulation of several lineage markers including CD206, CD163 
and CD64 and a shift in macrophage phenotype [34]. This downregulation in phagocytic 
receptors was of functional consequence since inhibition of the PDn-3 DPA biosynthetic pathway 
also significantly downregulated the ability of human macrophages to uptake apoptotic cells, a 
key pro-resolving action [36,37]. Of note, this alteration in macrophage phenotype and function 
was recovered with the reconstitution of components within the PDn-3 DPA pathway. Incubation of 
human monocyte-derived macrophages with either PD1n-3 DPA or 16S, 17S-epoxy-PDn-3 DPA led to 
a restoration of several phagocytic receptors and increased macrophage efferocytosis. 
Furthermore, administration of PD1n-3 DPA to ALOX15 deficient mice also restored the phenotype 
and efferocytic activity of macrophages in vivo [34]. Thus, these findings identify the PDn-3 DPA 
pathway as a component in the monocyte-to-macrophage differentiation program that regulates 
their phenotype and function. 
 
 
RvTs are produced during the early stages of acute inflammation and temper host 
immune responses 
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Recent studies have described and characterised a new family of bioactive mediators 
produced from n-3 DPA. This new family of four resolvins is termed the 13-series resolvins 
(RvT) given that all four molecules display potent host protective actions and carry a hydroxyl 
group on carbon 13 [38]. RvTs are biosynthesized from n-3 DPA in a process that requires both 
endothelial cell COX-2 and neutrophil lipoxygenase (ALOX) activity. The role for ALOX enzymes 
in the biosynthesis of RvT was established using heavy oxygen incorporation [38] with the 
identity of the ALOX enzymes catalyzing this reaction remaining of interest.  
During acute inflammation, cytokines such as TNF-α and IL-1β are released, activating 
endothelial cells that upregulate the expression of COX-2. Endothelial COX-2 converts n-3 DPA 
to 13R-hydro(peroxy)-docosa-7Z,10Z,14E,16Z,19Z-pentaenoic acid (13R-HpDPA); 13R-HpDPA 
or its reduced alcohol form 13R-hydroxy-docosa-7Z,10Z,14E,16Z,19Z-pentaenoic acid (13R-
HDPA) is then donated to neutrophils during neutrophil-endothelial cell interactions, whereby it 
is first converted to 7-hydro(peroxy)-13R-hydroxy-docosa-8,10Z,14E,16Z,19Z-pentaenoic acid 
[38]. This molecule can then undergo a second lipoxygenation reaction to yield 7,13R,20-
trihydroxy-docosa-8E,10Z,14E,16Z,18E-pentaenoic acid that was coined as RvT1. The 
hydroperoxide can also, in a lipoxygenase-dependent manner, undergo an epoxidation reaction 
to yield the allylic epoxide 7,8-11- epoxy-13R-hydroxy-docosa-9,11,14E,16Z,19Z-pentaenoic 
acid. This is then enzymatically hydrolysed to 7,12,13R-trihydroxy-docosa-8Z,10E,14E,16Z,19Z-
pentaenoic acid and 7,8,13R-trihydroxy-docosa-9E,11E,14E,16Z,19Z-pentaenoic acid, coined 
RvT2 and RvT3, respectively. Finally, 7-hydro(peroxy)-13R-hydroxy-docosa-
8,10Z,14E,16Z,19Z-pentaenoic acid is also reduced to 7,13R-dihydroxy-docosa-
8,10Z,14E,16Z,19Z-pentaenoic acid that is coined RvT4 (Figure 3).  
RvTs are produced in humans during exercise, that is now seen as a self-resolving 
inflammatory state, marked by an increase in neutrophil-endothelial interactions with 
upregulation of plasma RvT [38]. These mediators are also produced during infection when RvT 
levels are upregulated in plasma from septic patients when compared to healthy volunteers. 
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RvTs are protective in mice during acute inflammation where a mixture of RvT1, RvT2, RvT3 
and RvT4 immediately before or 2 hours after intraperitoneal Escherichia coli inoculation 
resulted in host-protection, increasing survival by >60%. Indeed, RvT limited neutrophil 
recruitment to the site of inflammation, increased phagocytosis and intracellular ROS levels and 
upregulated macrophage efferocytosis. Of note, the protective actions of RvTs were found to 
result from the reprogramming of the innate host response since RvT did not display direct 
bactericidal actions at biologically-relevant concentrations. Additionally, RvT reduced monocyte 
and macrophage expression of inflammasome components, decreasing caspase-1 and IL-1β 
expression and lactate dehydrogenase activity, a marker of pyroptosis. RvT also reduced 
peripheral blood platelet-leukocyte aggregates, an observation associated with reduced 
systemic inflammation. Exudate macrophage efferocytosis was also increased and a significant 
reduction in local and systemic eicosanoid levels was found in mice given RvT [38].  
Using a total organic synthetic approach, we recently established the complete 
stereochemistry and biosynthetic role of 13R-HDPA in the RvT pathway [39]. Chirally pure 
precursors were used in conjunction with stereoselective reactions that installed the 
configuration at the carbon 13 atom as R and formed geometrically pure double-bond moieties.  
Synthetic 13R-HDPA was matched with biogenic 13-HDPA, obtained by incubating n-3 DPA 
with human recombinant COX-2. Structural evaluation of synthetic 13R-HDPA and biogenic 13-
HDPA was carried out using liquid chromatography tandem mass spectrometry (LC-MS/MS) to 
attain MRM chromatograms to match retention times and MS-MS spectra to identify matching 
daughter ions. Chiral LC-MS/MS was used to confirm the stereochemistry around carbon 13, 
and UV-Vis spectrophotometry was used to match the double bond conjugation system. 
Incubation of the synthetic material with human leukocytes demonstrated that this was rapidly 
converted to all four RvTs [39]. These findings confirmed that the stereochemistry around the 
hydroxyl group on carbon 13 was in the R orientation and the double bond geometry around the 
conjugated double bond system was found to be in E, Z with the complete stereochemistry 
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established as 13(R)-hydroxy-7Z,10Z,13R,14E,16Z,19Z-docosapentaenoic acid as well as the 
role of this intermediate in the RvT biosynthetic pathway. 
 
RvT mediate the biological actions of statins in infectious-inflammation and inflammatory 
arthritis 
SPMs are implicated in mediating the protective actions of a number of clinically relevant 
therapeutics including aspirin and statins, whereby aspirin initiates the biosynthesis of epimeric 
forms of SPMs [40], while lovastatin, for example, upregulates the biosynthesis of 15-epi-LXA4 
[41]. In addition, atorvastatin was recently found to increase RvT formation during human 
neutrophil-endothelial cell interactions, as well as in mice during infections. This increase in RvT 
production resulted from the S-nitrosylation of COX-2 leading to increased 13R-HDPA levels, 
suggesting that the S-nitrosylation of COX-2 increased catalytic activity of the enzyme. This 
finding was in concordance with the S-nitrosylation of COX-2 cysteine residues in the presence 
of atorvastatin [38]. Inhibition of inducible nitric oxide synthase (iNOS) by L-NG-nitroarginine (L-
NAME) reduced the atorvastatin-mediated increases in peritoneal RvT levels after E. coli 
inoculation. A similar reduction was observed when mice were given celecoxib, a COX-2 
specific inhibitor. This highlights the complex regulatory axis of COX-2, as post-translational 
modification of the enzyme may yield mediators with distinct biological activities. In this context, 
aspirin acetylates COX-2 serine residues and inhibits the production of eicosanoids such as 
PGE2, PGD2 and TxB2, and upregulates the production of AT-LXA4. 
This mechanism was recently also found to be protective in arthritic inflammation where 
administration of atorvastatin upregulated RvT concentrations during inflammatory arthritis in 
both peripheral blood and joints [42]. Of note, this protective mechanism was not unique to 
atorvastatin and was shared with pravastatin. Atorvastatin administration during ongoing arthritis 
led to a 43% increase in total RvT amounts in arthritic paws compared to vehicle-treated mice. 
Pravastatin also increased paw RvT by ~20% with increases in RvT1 and RvT2.  
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These increases in joint RvT concentrations were also linked with decreases in tissue 
prostanoids and LTB4 concentrations. Prostaglandins were reduced by 20-40% by all statins 
tested when compared to vehicle. Exceptionally, PGF2α was reduced by ~75% in mice given 
pravastatin. LTB4 concentrations were reduced ~50% by atorvastatin and ~15% by pravastatin. 
Additionally, TxB2 was reduced 20-50% both statins [42].  The upregulation in RvT 
concentrations were linked with a reduction in disease severity where in mice administered 
atorvastatin, disease progression was dampened at day 4 post disease initiation, with disease 
scores reaching a maximum of 9.1 ± 1.2 at day 5 which was sustained until day 7. When mice 
were administered pravastatin, disease activity at day 5 was lower compared with mice 
administered vehicle, with a reduction in disease activity maintained until day 7 measured both 
as reduction in of clinical score and edema. In addition, both statins also lead to a reduction in 
joint damage at a histological level.  
In inflammatory arthritis atorvastatin and pravastatin administration also regulates both 
circulating and tissue resident leukocyte responses. In non-classical monocytes, atorvastatin 
reduced the expression of CD11b by ~18% and platelet-monocyte aggregation (measured by a 
decrease in CD62P) was reduced by ~24% compared to mice given vehicle [42]. Pravastatin 
significantly reduced platelet-monocyte aggregation by ~35%, and decreased CD11b 
expression by ~10%. In classical monocytes, expression of CD11b and CD62P were 
significantly reduced by ~42% and ~34% respectively in mice given atorvastatin compared to 
mice given vehicle. In mice given pravastatin, CD11b expression was decreased by ~40% and 
platelet-monocyte aggregation reduced by ~35%. Compared to vehicle, neutrophil activation 
markers were significantly reduced by atorvastatin and pravastatin, reducing CD11b expression 
by ~30% and platelet-neutrophil aggregation by ~24%. Of note, administration of celecoxib that 
inhibits the upregulation of RvT by pravastatin and atorvastatin reverses the protective actions 




The identification of n-3 DPA as a substrate to novel, structurally distinct, mediators that display 
potent host protective activities demonstrates that complex mediator networks become activated 
during acute inflammation to ensure tissue homeostasis. This is further underscored by the 
observation of a selective regulation of distinct lipid mediator pathways in a tissue and cell 
specific manner. In addition, mounting evidence suggests that some of the beneficial actions of 
a number of widely used drugs, including statins, is mediated via the regulation of these 
protective pathways. Given the potent actions of n-3 DPA-derived SPMs in regulating systemic 
and peripheral inflammatory responses, utilizing analogues and mimetics may be useful 
therapeutics in the prevention and treatment of chronic inflammatory diseases. In addition, 
strategies to boost their endogenous production potentially via supplementation with n-3 DPA 
may also be useful in controlling inflammation. While the clinical evidence for this approach is 
currently limited, recent studies in healthy volunteers provide evidence for the utility of this 
approach, whereby administering of n-3 DPA was found to upregulate peripheral blood 
concentrations of RvD5n-3 DPA [43]. Future studies will need to determine which patient populations 
will be responsive to this approach and which supplement forms will be effective in regulating n-
3 DPA-derived SPM concentrations. In this context, changes in their tissue concentrations with 
both disease and treatment suggest that these pathways may also be useful as biomarkers in 
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Figure 1: Diurnal changes in RvDn-3 DPA regulates peripheral blood leukocyte and platelet 
activation protecting from cardiovascular disease. In peripheral blood diurnal changes in 
acetylcholine (ACh) upregulates 15-lipoxygenase (ALOX15) activity promoting RvDn-3 DPA 
biosynthesis that limit the physiological activation of monocytes, neutrophils and platelets during 
the early morning hours. Increases in circulating adenosine concentrations in patients with 
cardiovascular disease inhibit ALOX5 activity disrupting the diurnal changes in plasma RvDn-3 
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Figure 2: PDn-3 DPA biosynthetic pathway and its regulation of monocyte-derived 
macrophage phenotype and function. In the PDn-3 DPA pathway n-3 DPA is converted to 17-
HpDHA and then to 16S, 17S-epoxy-PDn-3 DPA by either ALOX15 or ALOX15B. This is then 
hydrolyzed by epoxide hydrolase activity to PD1n-3 DPA and PD2n-3 DPA. This pathway regulates 























Figure 3: RvT biosynthesis and actions in mediating the protective actions of statins in 
infections and inflammatory arthritis. Production of RvT is initiated via the conversion of n-3 
DPA by the endothelial COX-2 expression yielding 13-HpDHA, that can then be converted to 
13-HDHA and donated to neutrophils where via ALOX activity this is converted to RvT1-4. Statin 
mediated S-nitrosylation of COX-2 upregulates 13-HDPA production contributing to the 
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